Clinical Trial Update: Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Child And Adolescent Outpatients With Major Depressive Disorder [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating desvenlafaxine succinate sustained-release for major depressive disorder in child and adolescent outpatients completed and posted res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Desvenlafaxine succinate sustained-release (DVS SR) (desvenlafaxine succinate)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Depression, Major Depressive Disorder | Phase 2 | Status: COMPLETED | Results posted: 2011-02-21